is reading and analyzing
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The fact that it's MRI safe is a big selling point. Not having to remove and reinsert the old-style blade retractors, thereby saving 45 minutes and reducing tissue damage and internal bleeding risk.
It'll bounce. The dips never last long. Anyone willing to post an L2 screenshot?
India would be a slam-dunk. I'm hoping the approval for Russia goes through soon. Once you get Russia, some of the smaller EU countries tag along as well.
Not a bad start.
Some companies choose not to launch an email or IR campaign until they have a verified product. With patents, FDA approval, 100s of hospitals using the product, gold stars from independent organizations, etc, I don't think there's a question of whether it's a legitimate product.
It's not a question of being able to afford an ad campaign either; the Harbinger report alone was <25k.
IMO, this is honestly a case of investors wanting to making money in the long run off of a solid company, not a 3 day pump and dump.
Great info there. The TA definitely looks like a double bottom IMO.
LOL. I was eating lasagna when I saw the pictures for VBAS. I'm sure the medical community can appreciate it, but..
If they're anything like the last financials, they certainly won't hurt.
Mark me and send me your picks (not pics). I'll hit you back.
C'mon power hour, let's kick this into high gear!
"Over fifteen years of clinical research, it has been shown that in approximately 70% of cases patients using NovaVision's VRT system over a three to six month period experience significant recovery in at least one functional outcome. In many cases this
recovery is enough to restore lost abilities such as reading, avoiding unseen objects while walking, or in some cases even driving a car."
Good info there stevo. It's amazing how simple it is. Engaging the plasticity of the brain by using lights to stimulate the parts that were damaged.
VYCO up 10% out of the gate. Rated STRONG BUY by independent researcher:
VYCO up 10%. Thin to .025!
VYCO green right out of the gate. Longs kickin' back.
Green right out of the gate. Git some!
Steady accumulation by smart investors. Buying in little parcels is the way to go before this takes off, IMO.
Nothing but buys today ladies and germs.
Haha, point taken. I feel the same way about LaGuardia.
Usually I just add 2 zeros to the end of the number on the L2 screen to find the actual amount of shares requested. Beyond that, not sure.
Safe travels to you.
VYCO super thin at .0195 x .02 Steady accumulation all day
VYCO thin at .0195 x .02 Technology restores lost eyesight to stroke and brain damage victims!
http://player.vimeo.com/video/39903199
VYCO super thin at .0195 x .02 Steady accumulation all day
Hello mac, can you post a screenshot?
More buys. We might actually see yesterday's volume. A lot of new investors buying up small parcels from the looks of it. Eyes are being opened.
VYCO has been seeing some accumulation spikes these past few days. Nibblers are getting their fins wet, while the longs have been basking in the shallows.
That's why VYCO received the STRONG BUY rating by Harbinger Research.
Explanation of the "STRONG BUY" rating by Harbinger Research
...and a few more getting their feet wet with some buy-ins. Nothing wrong with testing the water.
Steady accumulation. How much is left at CSTI?
Welcome to the VYCO board, Prodigy. Lots of solid DD on a solid company to be found here. If you're in a hurry, here's the vid
http://player.vimeo.com/video/39903199
If you want a beefy piece of DD, here's the indy report
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
Good closing, now we've just got to start at .019 or higher tomorrow.
VYCO: You can't argue with an independent report
Based on solid near-term growth prospects and extreme upside in potential in 2013 and
beyond, we are initiating coverage of Vycor with a Strong Buy rating and a target price range
of $0.05 per share. Assuming the Company executes on its plan over the next 12-18 months,
we believe its current valuation multiple of just 4.2x our 2013 revenue forecast is far too low,
and believe a multiple in the 12x to 15x range is more appropriate. Furthermore, we see upside
to our estimates if NovaVision is able to achieve market penetration more quickly than we
foresee.
http://a.eqcdn.com/harbingerresearch/media/b767cf61ff1d00bcf70bf414fab946a5.pdf
VYCO spikes on low float and amazing products for the medical community. NovaVision restores sight, VBAS makes some inoperable conditions possible.
http://player.vimeo.com/video/39903199
I don't see any thing to worry about either. I've paid my dues on some real bombs, so I'd like to think I'm more cautious now.
I'm still curious as to the float on this one. It spikes with a relatively small investment. Not only is it a long play, but it's a good trading vehicle as well.
As the good book says "ASK and you shall receive, BID, and you may be waiting awhile"
My VYCO stock went up today. Check the board and the DD and you'll see why.
It's no wonder VYCO is taking off today:
-200% increase in revenues in a $20B international market
-Strong international patent suite to proprietary technology
-Legit endorsement from medical and scientific community. They have Harvard Med School Professors on the advisory board
-Technology that literally restores sight to the blind and makes inoperable brain procedures possible, 2000 medical procedures already performed
- Market gaining momentum WITHOUT promo's. 14xs the average volume -Competition is largely non-existent
-VBAS lauded in peer reviewed journals at Johns Hopkin's University, Cleveland Clinic, University of Illinois as technically superior
- Over fifteen years of clinical research, it has been shown that in approximately 70% of cases patients using NovaVision's VRT system over a three to six month period experience significant recovery in at least one functional outcome. In many cases this
recovery is enough to restore lost abilities such as reading, avoiding unseen objects while walking, or in some cases even driving a car.
Yes! VYCO up 33% on organic awareness alone!
VYCO spread thinning at .017 x .020. You need to see what all the fuss is about!